 **Gonorrhoea Standing Order**

|  |  |  |  |
| --- | --- | --- | --- |
| Issue date: |  | Review date: |  |

This standing order is not valid after the review date. The review date is one year after the date the order was signed by the issuer.

|  |  |
| --- | --- |
| **Standing Order Name** | Gonorrhoea |
| **Rationale** | To promptly and appropriately treat patients with gonorrhoea and follow-up of contacts |
| **Scope (condition and patient group)** | Adult patients presenting with a diagnosis of gonorrhoea or have had unprotected sex with someone who has been treated with gonorrhoea. |
| **Red Flags** | Differential diagnosis with other sexual transmitted diseases. |
| **Assessment** | * This Standing order should be followed when Gonorrhoea has already been confirmed by laboratory testing or to treat unprotected sexual contacts of those patients with a confirmed diagnosis of gonorrhoea.
* For more information about assessment go to http://www.nzshs.org/guidelines

Asymptomatic females:* vulvovaginal NAAT swab for trichomoniasis, chlamydia and gonorrhoea
* Additional anorectal NAAT swab as indicated based on sexual history

Symptomatic females:* vulvovaginal NAAT swab for trichomoniasis, chlamydia and gonorrhoea then
* a speculum examination and endocervical culture swab

Symptomatic males:* Take a urethral culture swab, followed by first void urine for NAAT testing

Asymptomatic male contacts:* Do not require screening for urethral gonorrhoea if asymptomatic
 |
| **Indication** | **Treatment of diagnosed gonorrhoea infections or the contacts of patients with a diagnosis of gonorrhoea** |
| **Medicine** | **Azithromycin** 500mg tablets (to be given with ceftriaxone) |
| **Dosage instructions** | 1 g immediately |
| **Route of administration** | Oral |
| **Quantity to be given** | 2 x 500mg tablets |
| **Contraindications** | Concomitant colchicine in patients with hepatic or renal impairment (increased risk of colchicine toxicity) |
| **Precautions** | * Warfarin—monitor INR 3 days after starting antibiotics
* Multiple drug to drug interactions- check
* Pregnancy- category B1
 |
| **AND Medicine** | **Ceftriaxone with 1% lignocaine** (to be given with azithromycin) |
| **Dosage instructions** | 500mg intramuscularly immediately |
| **Route of administration** | Intramuscular  |
| **Quantity to be given** | 1 x 500mg vial |
| **Contraindications** | Allergy to cephalosporins. Avoid as a treatment option in patients who have a genuine, immediate, or severe hypersensitivity to penicillin or other beta-lactam drugs. |
| **Precautions** | BreastfeedingRenal or hepatic impairmentPregnancy –category B1 |
| **Additional information** | Discuss need to contact sexual partners/contacts for treatmentAdvise to abstain from sex until abdominal pain (if present) has settled, and to abstain from sex, or use condoms, until 7 days after all sexual contacts have been treated.Discuss all suspected gonorrhoea cases with doctor or sexual health nurse (alongside treatment) |
| **Follow-up** | * Follow-up (phone or in person) 7 days after treatment to ensure
	+ Symptom resolution, give results,
	+ All notified contacts informed?
	+ Completed/tolerated medication?
	+ Any unprotected sex in the last week?
* Any risk of reinfection? Re-treatment necessary if re-exposed to untreated contact
* Reinfection is common, offer repeat sexual health check in 3 months.
* A test of cure is only needed when symptoms don’t resolve or if pharyngeal infection.
 |
| **Countersigning and auditing** | Countersigning is not required. Audited monthly.**OR** Countersigning is required within ***XX*** days |
| **Competency/training requirements** | All nurses working under this standing order must be signed off as competent to do so by the issuer and have had specific training in this standing order. |
| **Supporting documentation** | Healthpathways at [www.healthpathways.org.nz](http://www.healthpathways.org.nz) Best Practice Journal at [www.bpac.org.nz](http://www.bpac.org.nz) New Zealand Formulary at [www.nzf.org.nz](http://www.nzf.org.nz) Individual medicine data sheets at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) The New Zealand Sexual Health Society Incorporated [www.nzshs.org](http://www.nzshs.org) Standing Order Guidelines, Ministry of Health, 2012Medicines (Standing Order) Regulations 2012 (Standing Order Regulations) |
| **Definition of terms used in standing order** | Category B1 - Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |

|  |  |
| --- | --- |
| **Medical Centre or Clinic:** |  |

|  |
| --- |
| **Signed by issuers** |

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |
| --- |
| **Nurses operating under this standing order** |

Only Registered nurses working within the above medical centre or clinic are authorised to administer medication under this standing order.

We the undersigned agree that we have read, understood and will comply with this standing order and all associated documents.

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_